Considering the alleged role played by TLR4 in BP modulation in animal models of hypertension, we sought to investigate whether systemic blockade of this receptor with a neutralising TLR4 antibody would impact MAP in STZ-induced diabetic animals (Fig. 1). The gene discussed is TLR4; the disease is hypertensive disorder.